Molson Coors Says ‘Volatile Times,’ Not Ozempic, Dim Its Beer Outlook

Molson Coors Brewing Co.’s more cautious outlook for beer consumption isn’t coming from the new class of weight-loss drugs, which some have speculated would dent the alcohol industry, its chief executive officer said.

“We don’t have data to suggest that’s having a meaningful impact on the alcohol space,” CEO Gavin Hattersley said on an earnings call Tuesday. “I do think we’re living in more volatile times.”